- Conditions
- Chronic Lymphocytic Leukemia (CLL), Waldenstr(SqrRoot)(Delta)m s Macroglobulinemia, Mantle Cell Lymphoma, Sudden Cardiac Death, Cardiac Arrhythmias, Hematologic Malignancies
- Interventions
- Not listed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 110 Years
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 11,013
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Sickle Cell Disease
- Interventions
- Interviews and Surveys
- Other
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 12 Years to 70 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Ischemic Heart Failure
- Interventions
- Placebo, 30 mg dose of JVS-100, 45 mg dose of JVS-100
- Biological
- Lead sponsor
- Juventas Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Gainsville, Florida • Cincinnati, Ohio + 1 more
- Conditions
- Copd
- Interventions
- Interprofessional Education (IPE), Usual care
- Other
- Lead sponsor
- Baystate Medical Center
- Other
- Eligibility
- 23 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Springfield, Massachusetts
- Conditions
- HIV, HIV Infections, Acquired Immunodeficiency Syndrome
- Interventions
- TAF, Placebo, E/C/F/TAF, Current failing ARV regimen, ATV
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 5
- States / cities
- Ft. Pierce, Florida • West Palm Beach, Florida • Wilton Manors, Florida + 2 more
- Conditions
- Solid Tumor, Adult
- Interventions
- GAd-209-FSP low dose, MVA-209-FSP low dose, GAd-209-FSP high dose, MVA-209-FSP high dose, GAd20-209-FSP, RP2D, MVA-209-FSP, RP2D, KEYTRUDA®
- Biological · Drug
- Lead sponsor
- Nouscom SRL
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 13
- States / cities
- Duarte, California • Irvine, California • Los Angeles, California + 9 more
- Conditions
- Pediatric ALL
- Interventions
- ZTI-01 100 mg/kg, ZTI-01 75 mg/kg
- Drug
- Lead sponsor
- Nabriva Therapeutics AG
- Industry
- Eligibility
- Up to 11 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 5
- States / cities
- Orange, California • San Diego, California • Louisville, Kentucky + 2 more
- Conditions
- Glaucoma
- Interventions
- Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5%, Sham Procedure, placebo eye drops
- Drug · Procedure · Other
- Lead sponsor
- Glaukos Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 510 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Dothan, Alabama
- Conditions
- Neuroblastoma Recurrent
- Interventions
- Temozolomide, Irinotecan, hu14.18K322A, N803, Sargramostim
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 30 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 5
- States / cities
- San Francisco, California • Aurora, Colorado • Ann Arbor, Michigan + 2 more
- Conditions
- Intraoperative Ureter Injury
- Interventions
- Nerindocianine for Injection
- Drug
- Lead sponsor
- Li-Cor, Inc.
- Industry
- Eligibility
- 19 Years and older · Female only
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Shoulder and Upper Arm Injury
- Interventions
- Not listed
- Lead sponsor
- Texas Woman's University
- Other
- Eligibility
- 18 Years to 30 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Osteoarthritis, Knee
- Interventions
- PF-04191834, PF-04191834 placebo, Naproxen placebo, Naproxen
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 25
- States / cities
- Peoria, Arizona • Phoenix, Arizona • Anaheim, California + 20 more
- Conditions
- Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
- Interventions
- ONC-392, Pembrolizumab, Docetaxel
- Drug
- Lead sponsor
- OncoC4, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 733 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 33
- States / cities
- Springdale, Arkansas • Davis, California • Downey, California + 27 more
- Conditions
- Infertility, Infertility, Female, Infertility, Male
- Interventions
- Insemination with the Mosie Baby Kit
- Device
- Lead sponsor
- Mosie Baby
- Industry
- Eligibility
- Not listed
- Enrollment
- 350 participants
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Sexually Transmitted Infections
- Interventions
- STI/HIV Intervention Behavioral Intervention Program
- Behavioral
- Lead sponsor
- Madigan Army Medical Center
- Federal
- Eligibility
- 18 Years to 30 Years
- Enrollment
- 155 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2024
- U.S. locations
- 2
- States / cities
- Fayetteville, North Carolina • Tacoma, Washington
- Conditions
- Sepsis
- Interventions
- Daptomycin
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 48 Hours to 120 Days
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Ductal Carcinoma In Situ, Breast Fibrocystic Change, Breast Lobular Carcinoma In Situ, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
- Interventions
- Abemaciclib, Therapeutic Conventional Surgery
- Drug · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Acute Coronary Syndrome, Multi Vessel Coronary Artery Disease, Ischemic Stroke
- Interventions
- Life and Medication Recommendations
- Behavioral
- Lead sponsor
- LifeBridge Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Schizophrenia
- Interventions
- Risperidone-SABER, ZX003:risperidone-SABER and the DosePro System
- Drug · Other
- Lead sponsor
- Zogenix, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Pain, Intractable, Pain, Chronic
- Interventions
- Commercially available neurostimulation systems
- Device
- Lead sponsor
- MedtronicNeuro
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 10
- States / cities
- Carlsbad, California • Fort Myers, Florida • Edina, Minnesota + 7 more
- Conditions
- Patent Ductus Arteriosus, Preterm Infant, Bronchopulmonary Dysplasia, Neurodevelopmental Abnormality
- Interventions
- Not listed
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- Up to 72 Hours
- Enrollment
- 526 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 4
- States / cities
- Columbus, Ohio
- Conditions
- Advanced Solid Tumor
- Interventions
- BG-75098, BGB-43395, Fulvestrant
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • New Haven, Connecticut • Baltimore, Maryland + 3 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Docetaxel/Carboplatin/Bevacizumab/Erlotinib, Docetaxel/Carboplatin
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 26
- States / cities
- Anniston, Alabama • Jonesboro, Arkansas • Fort Myers, Florida + 20 more
- Conditions
- Infections, Human Immunodeficiency Virus and Herpesviridae
- Interventions
- GSK1349572, Efavirenz
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Buffalo, New York